Keeping mTORC1 switched on does not grow muscle evenly — fibre types diverged
In short
High-resolution spatial transcriptomics applied to a mouse model of mTORC1 hyperactivation found the growth signal did not enlarge muscle uniformly. Type I and IIa fibres were largely resistant to pathology. Type IIx fibres diverged: in soleus they enlarged abnormally under sustained growth signalling with impaired proteostasis, while in extensor digitorum longus they shifted into an entirely different metabolic profile. Macrophages and fibroblasts accumulated in soleus, forming a fibrotic microenvironment. This is a genetic hyperactivation model, not training.
mTORC1 is the pathway that initiates muscle protein synthesis, which makes it the most name-checked molecule in lifting. Supplement marketing generally treats it as a volume knob: turn it up, grow more. This study shows why that picture is wrong.
Researchers applied histopathology and high-resolution spatial transcriptomics together to a mouse model of sustained mTORC1 hyperactivation, because conventional approaches cannot link histopathological features to molecular states at single-fibre resolution. They profiled cross-sections from two muscles with distinct fibre-type compositions: extensor digitorum longus and soleus.
Did every fibre respond the same way?
No, and that is the finding. mTORC1 hyperactivation elicited distinct, fibre-type-dependent pathological programmes. Type I and IIa fibres were largely resistant, showing relatively limited morphological alteration.
Type IIx fibres, meanwhile, diverged into opposing fates. In soleus they underwent abnormal enlargement associated with sustained growth signalling, cytoskeletal remodelling and impaired proteostasis. In extensor digitorum longus the same fibre type developed basophilia, with increased RNA content and lipid, oxidative and nucleotide metabolism signatures — a completely different state. Within extensor digitorum longus, even type IIb fibres split into discrete transcriptional states.
Bigger is not the same as better
Look again at the soleus result. The fibres did get bigger. But proteostasis was impaired in the same place. On top of that, non-myocyte populations — macrophages and fibroblasts — accumulated preferentially in soleus, forming a fibrotic microenvironment combining inflammation, remodelling and hypertrophy.
So the result of leaving the growth signal on was not "more muscle". It was "different pathology depending on the muscle and the fibre type". The enlargement observed here is not the same thing as training-induced hypertrophy.
This work used mice genetically engineered for constant mTORC1 hyperactivation — a disease model. Training switches the pathway on and back off; this model leaves it on. The findings therefore cannot be transferred directly to human training or supplement effects. What transfers is the concept, not any number.
So what is worth taking from it?
Two things. First, a growth pathway is not a dial. The same signal produced entirely different outcomes across fibre types and muscles, which is why a product claiming to "activate mTOR" is not thereby claiming to build muscle.
Second, it is a question of measurement resolution. The reason this study went down to single fibres is that at whole-muscle scale, opposing changes cancel out and become invisible. Muscle is not a homogeneous tissue.
How this relates to your strength score
This study is about how heterogeneous the inside of a muscle is — and a relative strength score sits at the opposite end of that. It does not inspect molecular state. It asks whether the barbell went up. That is a feature. Whatever is happening fibre by fibre, your squat, bench and deadlift integrate all of it into a single output. Which is why, when judging whether a supplement or a protocol is worth anything, the total three months later is a far more trustworthy signal than the name of a pathway.
On how far size and strength actually overlap, see muscle growth and strength.
Frequently asked questions
What is mTORC1?
It is the intracellular signalling pathway that initiates muscle protein synthesis. Resistance training activates it, which is why it comes up constantly in discussions of muscle growth and in supplement marketing.
Does more mTORC1 activation mean more muscle?
It is not that simple. In a mouse model of sustained mTORC1 hyperactivation, type I and IIa fibres changed little, while type IIx fibres either enlarged abnormally with impaired proteostasis or shifted into an entirely different metabolic state depending on the muscle.
Does this apply to human training?
Not directly. The study used mice genetically engineered for constant mTORC1 hyperactivation. Training activates the pathway transiently and lets it return. Only the conceptual implication carries over.
Why do fibre types respond differently?
Skeletal muscle is a heterogeneous tissue of different fibre types and non-myocyte populations. In this study even the same type IIx fibres moved in opposite directions in soleus versus extensor digitorum longus.
How should muscle growth be judged then?
By integrated output rather than pathway names. Whatever happens inside the muscle, Big 3 numbers and body composition tracked over several months combine those changes into something you can actually read.
Source: PubMed